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ABSTRACT
Alzheimer’s disease (AD), the most common form of neurodegenerative disorder,
is characterized by deposition of amyloid-β (Aβ) plaques in the brain. Aβ monomer
undergoes nucleation to form oligomers, then soluble aggregates, then fibrils which make
up the plaques. Aβ oligomer species are believed to be the most neurotoxic aggregate
species. Currently under investigation is a mechanism for Aβ removal from the brain,
across the blood-brain barrier (BBB). P-glycoprotein (P-gp) is a membrane-bound efflux
protein located on the apical, or blood, side of the BBB, which transports a wide variety of
substrates. Further complicating this potential clearance mechanism is the reduction of
P-gp cell surface expression in arteries exhibiting cerebral amyloid angiopathy (CAA), or
the buildup of amyloid plaques around the arteries.
P-gp has been suggested as a potential Aβ clearance mechanism based on its ability
to transport a wide variety of amphipathic substrates even though experimental evidence
of Aβ transport via P-gp has been disputed. This study sought to examine and characterize
Aβ aggregate species interaction with P-gp.

Additionally, the potential deleterious

relationship between P-gp and extended Aβ presence was investigated.
Of the four different Aβ aggregate species tested, monomer, oligomer, sonicated
fibril, and fibril, only the Aβ oligomer demonstrated the ability to bind to P-gp. These Aβ
oligomers displayed a selective interaction with the R-binding site, and not the H-binding
site. However, this binding and interaction could not be confirmed in a cellular transport
assay.
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Extended Aβ aggregate species treatment at the apical surface of a cellular
monolayer revealed no change in either the cell surface expression of P-gp or the transport
capabilities of P-gp. Interestingly, when a cellular monolayer was treated from the
basolateral surface with Aβ aggregate species, the active P-gp driven net efflux decreased.
These results support interactions between Aβ oligomers and P-gp and motivate further
investigation of P-gp as a therapeutic clearance mechanism for Aβ.
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CHAPTER 1
BACKGROUND AND SIGNIFICANCE
1.1

Alzheimer’s Disease
Every 65 s someone develops Alzheimer’s disease (AD) in the US. Over 44 million

people worldwide have been diagnosed with AD, making it the most common
neurodegenerative disorder. As the population continues to age, these numbers are only
expected to increase in the coming years. AD is already the sixth leading cause of death
in the US. While the other top ten causes of death, including heart disease, cancer, HIV,
and stroke, have dramatically reduced their mortality rate since the year 2000, deaths from
AD have risen by 123%1. Additionally, AD is the only one of the top ten that is unable to
be cured, prevented, or slowed.
In 1906, Dr. Alois Alzheimer described a neurodegenerative condition, now known
as AD, which included symptoms of short-term memory loss and behavioral changes as
well as the presence of amyloid plaques and neurofibrillary tangles2,3. These plaques,
considered hallmarks of AD, are formed by the amyloid-β (Aβ) protein. Aβ monomer is
commonly found throughout the body and is non-toxic. While the function of Aβ monomer
is still under investigation, in the disease state, Aβ monomer nucleates to form oligomers,
a neurotoxic Aβ aggregate species4–15. Aβ oligomers continue the aggregation process to
form soluble intermediates, then Aβ fibrils, which make up the plaques11,16–23. While most
therapeutic strategies target this aggregation pathway18–20, this approach has not yet been
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successful; additional novel therapeutic targets are needed and one such target mechanism
is clearance24–27.
1.2

Transport Across the Blood-brain Barrier
The blood-brain barrier (BBB) is the single endothelial cell thickness making up

the capillary wall in the brain. While the capillary wall in other parts of the body is
semi-discontinuous to allow for the free exchange of molecules, the capillary wall of the
BBB is characterized by its tight junctions and high density of cells. These tight junctions
require most transport into and out of the brain to be active transport via membrane-bound
proteins28–30.
P-glycoprotein (P-gp) is a membrane-bound efflux protein located on the apical
side of the BBB, as well as in the intestine, liver, and kidneys31–38. P-gp, encoded by the
multi-drug resistance 1 (MDR1) gene39–43, evolved as a defense mechanism and transports
a wide variety of substrates44–47. It is a member of the ATPase binding cassette (ABC)
transport protein family, using energy obtained from the hydrolysis of ATP to transport
substrates into the capillary for removal through the vasculature48–55. The structure of P-gp
consists of two cassettes that share a 65% amino acid similarity. The N-terminal cassette
contains six transmembrane domains, followed by an ATP binding site, connected to the
C-terminal six transmembrane domains and ATP binding site55–60.
Most

P-gp

substrates

are

amphipathic

in

nature

and

include

many

chemotherapeutic, immunosuppressive, and anti-inflammatory agents in addition to
calcium channel blockers. Aromatic residues line the binding pockets, and it is thought the
hydrophobic region of a substrate binds to P-gp46,57,61–67. There are two well described
binding pockets, the H site and the R site, named for their fluorescent substrates61,65,68–71.
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The H-binding site binds and transports Hoechst 3334257,61,68,72,73, while the R-binding site
binds and transport Rhodamine 12334,46,61,66,68,74–77. When both sites are occupied, they can
work cooperatively, increasing the transport rate for each substrate compared to the
substrate’s transport rate alone65,68. This cooperative binding could be exploited in the
investigation of a potential therapeutic.
BBB in vitro models
Human brain microvascular endothelial cells (HBMVECs) are usually used to
model the BBB in vitro28,78–80. They form tight junctions in the presence of hydrocortisone
and grow easily into monolayers. However, it can be difficult to study P-gp in such a
system due to P-gp’s low relative expression.

Additionally, there are brain

microvasculature cell models from different species investigated alone or in co-culture to
create a BBB model, which exhibit similar difficulties in studying P-gp specifically.
Two non-brain microvasculature cell-based models used to study P-gp include
human epithelial colorectal adenocarcinoma (Caco-2) cells and Madin Darby canine
kidney (MDCK) cells37,81–84.

Over time, Caco-2 cells have been differentiated and

polarized to mimic cells in the small intestine, exhibiting tight junctions and expressing
transporter proteins such as P-gp. MDCK cells express a small amount of canine P-gp
naturally. However, these cells serve as a parental line to the MDCK-MDR1 cell line,
which has been transfected to overexpress human P-gp85. MDCK MDR1 cells have
relatively high human P-gp expression compared to other cell types and also express tight
junction proteins85–89. It has been demonstrated that both Caco-2 and MDCK-MDR1 cells
are reliable models of the BBB when compared to rat brain microvasculature endothelial
cells82. In this study, MDCK-MDR1 cells exhibited BBB properties, including tight
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junction proteins and P-gp expression, in 3-4 days, while the Caco-2 cells displayed BBB
properties in 19-21 days, and MDCK-MDR1 cells are more widely used in the literature as
a BBB model37,81–84,90–92.
1.3

Role of P-gp in AD
In 2004, a study of brain tissue obtained from non-demented elderly people showed

a local inverse correlation of the expression of P-gp and the deposition of aggregated Aβ
protein93,94. Vogelgesang et al correlated the level of P-gp expression with the level of Aβ
aggregation and cerebral amyloid angiopathy, or the deposition of Aβ around small and
mid-sized arteries. While the tissue samples all belonged to elderly subjects, the goal of
this study was to investigate early AD markers and trends, so samples for late stage
dementia patients were excluded. These findings insinuate P-gp may have an important
role to play in the AD disease state.
Using inverted vesicles made from CHRB30 cells, Lam et al measured Aβ in its
monomeric state as it was being transported across the plasma membrane25. These inverted
vesicles, where P-gp is oriented towards the bulk solution, were in solution with ATP and
either Aβ1-40 or Aβ1-42. Lam et al observed that the transport of either Aβ species across the
membrane was dependent upon the presence of both ATP and P-gp showing that Aβ is a
substrate of P-gp.
Moving to an in vitro model, Lam et al transfected cell lines that expressed varying
levels of P-gp to overexpress Aβ. The cells with the highest expression of P-gp excreted
the most Aβ. Wild type and P-gp knockout mice injected with both Aβ1-40 and Aβ1-42
showed increased clearance in the wild type mouse95. These studies and others suggest
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that Aβ clearance from the brain into the blood could be diminished by a decrease in
expression of P-gp at the BBB95–100.
Kuhnke et al studied the mediation of Aβ transport by P-gp by using cells cultured
in a monolayer to simulate the BBB101. Using fluorescently labelled Aβ1-40 and Aβ1-42, it
was determined P-gp facilitates the removal of both species. Additionally, Kuhnke et al
used a ThT fibrillogenesis assay to show the Aβ peptides transported across the cell
monolayer were not in a fibrillar form but were mostly soluble aggregates. This shows that
aggregated Aβ is also a substrate of P-gp.
1.4

Study Overview
Due to P-gp’s ability to transport a wide variety of amphipathic and hydrophobic

substrates, the most likely Aβ aggregate species able to be transported in Aβ oligomers.
Aβ oligomers are slightly amphipathic with concentrated hydrophobic amino acids at the
C-terminus. Aβ oligomers present a hydrophobic surface as evidenced by binding of
hydrophobic dyes20. Aβ oligomers are the only Aβ aggregate state with the ability to enter
the lipid bilayer, the preferred access to P-gp’s binding sites62,63. This study investigated
the hypothesis that P-gp preferentially binds and transports a specific Aβ aggregate state,
oligomers, out of the brain. However, this clearance mechanism may be disrupted with the
loss of P-gp in vessels containing cerebral amyloid angiopathy.

Thus, this study

additionally investigates the hypothesis that the presence of Aβ at the BBB can exasperate
the disease state by reducing levels of P-gp available at the cell membrane for transport.
To test these hypotheses, the binding and transport of Aβ by P-gp and the effect of Aβ on
the presence of P-gp were examined separately. These studies comprise the two aims of
this work and are described below.
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1.4.1 Aim 1: To Demonstrate the Selective Binding and Transport of Aβ Oligomers via
P-gp
The binding capability of Aβ by P-gp has been previously studied by a variety of
groups; however, the effect of various aggregate species of Aβ have not been considered.
This aim seeks to identify the Aβ aggregate species selectively binding to P-gp for transport
and then characterize that binding relationship. First, experimentation compares the
transport of Aβ aggregate species by P-gp across inverted P-gp membranes. Subsequently,
those species with the highest transport are characterized for binding site interaction using
MDCK-MDR1 cells by measuring the accumulation of a fluorescent substrate specific for
each of P-gp’s binding sites. P-gp has two well-described binding sites, the H-binding site,
characterized for its binding of Hoechst 33342, and the R-binding site, characterized for its
binding of Rhodamine 123.

Finally, transport across monolayers formed by

MDCK-MDR1 cells will be measured to assess the effect of Aβ aggregates on directional
transport of Rhodamine 123. Comparing transport across these cell monolayers will
quantify the role of P-gp in a biological system. The addition of alternative substrates with
well described binding sites of P-gp to this assay allows further description of the binding
relationship between Aβ and P-gp. These observations validate that P-gp is a viable target
of potential AD therapeutics.
1.4.2 Aim 2: To Elucidate the Effect of Aβ Aggregate Species on P-gp Cell Surface Levels
and Associated Transport
It has been shown that Aβ to P-gp binding can signal P-gp degradation in the cell102.
This aim investigated the Aβ aggregate species responsible for this action using
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MDCK-MDR1 cells to determine if the presence of Aβ aggregate species reduced the level
of P-gp on the cell surface. Immunocytochemistry was used to quantify P-gp available at
the cell membrane for transport, while cellular accumulation assays were used to verify the
transport abilities of that P-gp. Additionally, cells were treated at the basolateral surface
for a cellular transport assay to determine if the location of the Aβ treatment relative to the
cell’s polarity exposed any effect on the function of P-gp. These studies explore the
deleterious effect of Aβ aggregate species on the availability of P-gp on the cell membrane.
Fully describing the relationship between Aβ aggregate species and P-gp is necessary to
appropriately target P-gp with a potential AD therapeutic.
1.5

Innovation
Almost 250 potential drugs for the treatment of AD were tested in clinical trials

between 2002-2012(most recent data available). However, only one drug was successful,
bringing the current total number of drugs approved by the FDA available in the US to five
– Aricept, Razadyne, Namenda, Exelon, and Namzaric1. Additionally, instead of treating
the underlying disease state, each is only able to improve the symptoms of AD temporarily.
Previous studies concerning potential therapeutics in AD have targeted the
amyloidgenic aggregation pathway.

These possible therapeutics have investigated a

compound’s ability to alter the Aβ aggregate’s morphology and size to reduce the overall
neurotoxicity. Unfortunately, while many of these compounds have been tested, most fail
as drugs and have resulted in few clinical trials. This is hypothesized to result from the
low specificity and affinity of the Aβ inhibitors. In this study, a novel therapeutic target is
pursued by investigating an Aβ clearance mechanism. By targeting this pathway, the
presence of Aβ in the brain will decrease, resulting in a decrease in aggregation due to the
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process’ nucleation dependency. This decrease in aggregation should lead to a reduction
in neurotoxicity and a decrease in neurodegeneration. A comprehensive description of the
relationship between P-gp and Aβ aggregates will highlight a pathway for Aβ clearance
from the brain via transport across the BBB. In addition, as potential therapeutics would
be acting on the BBB, instead of having to cross the BBB and act on the brain, the relevant
bioavailability of a potential therapeutic will be higher.
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CHAPTER 2
MATERIALS AND METHODS
2.1 Materials
Aβ1-40 was purchased from Bachem (Torrence, CA) or AnaSpec, Inc. (San Jose,
CA). Aβ1-42 was obtained from AnaSpec, Inc. Thincert membranes and cell culture 6-well
and 24-well plates were obtained from Grenier Bio-one (Kremsmünster, Austria). P-gp
inverted vesicles and cell culture 96-well plates were purchased from Corning (Corning,
NY). Anti-P-gp (P7965) was purchased from Millipore Sigma (Burlington, MA). Normal
Donkey serum and Cy3 was purchased from Jackson Immunoresearch (West Grove, PA).
Other chemicals were purchased from VWR (Radnor, PA).
2.2 Preparation of Aβ1-40 Monomer
Lyophilized Aβ1-40 was purified to obtain monomeric protein prior to use in
experiments. Fast protein liquid chromatography (FPLC) that utilizes size exclusion
chromatography (SEC) on a Superdex 75 HR 10/300 column (GE Healthcare, Piscataway,
NJ, USA) was used to remove any seeds from which aggregates can grow. Prior to
injection, Aβ1-40 was reconstituted in 50 mM NaOH at 2 mg/mL to minimize the formation
of small aggregates. The system was pretreated with 2 mg/mL BSA in order to aid in the
reduction of nonspecific Aβ interaction with the column’s dextran matrix. Protein elution
occurred in 100 mM HEPES Tris buffer (pH 7.4). Aβ1-40 monomer concentration was
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calculated using the extinction coefficient of 1450 M-1 cm-1 at 276 nm21 and Beer-Lambert
law. Purified Aβ1-40 monomer was used fresh in assays and for aggregation into Aβ1-40
fibrils.
2.3 Preparation of Aβ1-42 Oligomer
Aβ1-42 was solubilized in cold HFIP at 4°C for 1 h. The solution was then aliquoted
and the HFIP was allowed to evaporate overnight at 25°C. Protein films were stored
at -80°C until use. Dried films of Aβ1-42 were resuspended in DMSO at a concentration of
1.5 mM. For the in vitro assays, protein was diluted to 30 μM in 100 mM HEPES-Tris
buffer (pH 7.4) containing 1 μM NaCl to initiate oligomerization. After 15 min, the
reaction solution was diluted for use. For cellular based assays, protein was diluted to
15 μM in 12 mM phosphate buffer (pH 7.4) containing 1 μM NaCl. After 30 min, the
reaction solution was diluted for use.
2.4 Preparation of Aβ1-40 Fibril
SEC-purified Aβ1-40 monomer was diluted to 60 μM in 100 mM HEPES-Tris buffer
(pH 7.4) containing 250 mM NaCl (physiological salt condition) and continuously agitated
(800 rpm) until the presence of Aβ1-40 fibrils was confirmed. To verify, aliquots of the
aggregation mixture were removed and diluted in a 7-fold excess of thioflavin T (ThT).
ThT is a fluorescent dye that has an enhanced shift in fluorescence in the presence of
amyloid’s β-sheet structure. Measurements of the fibril mixture were taken using a LS-45
luminescence spectrometer (Perkins Elmer, Inc., Waltham, MA) with an excitation of
450 nm. Fluorescence was calculated by the integration of fluorescence emission spectra
from 470 nm to 500 nm and was used to calculate the concentration of fibrils present by
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comparing the area under the curve for the aggregation mixture to the area under the curve
for the fraction of insoluble fibrils. To produce smaller aggregates, an aliquot of fibrils
was sonicated for 5 min. Sonicated Aβ1-40 fibrils and Aβ1-40 fibrils were used fresh in
assays.
2.5 ATPase Assay
An ATPase assay was used to quantify binding of Aβ to P-gp. When a ligand binds
to P-gp, ATP is hydrolyzed and inorganic phosphate (Pi) is released. P-gp is exclusively
an efflux transporter; therefore, in this assay flipping the protein-membrane conjugate
allows for substrate transport into a vesicle and presentation of P-gp to the bulk solution.
Aβ samples and controls, containing either vehicle (negative control) or
20 μM verapamil (positive control), were prepared in 100 mM HEPES-Tris assay buffer
(pH 7.4) containing 50 mM KCl, 2 mM DTT, 2 mM EGTA, and 5 mM sodium azide. All
samples were prepared with or without 100 μM NaOV, which blocks the ATP binding site
to prevent transport of potential substrates, then combined with inverted vesicles
containing 20 μg P-gp (Corning) on a 96-well plate and incubated (37°C, 7 min).
4 mM MgATP was added to each well to initiate active transport via P-gp. After an
additional incubation (37°C, 20 min), 30 μL 10% SDS stopped the reaction. To quantify
Pi present, 200 μL coloring reagent, 35 mM ammonium molybdate, 15 mM zinc acetate,
10% ascorbic acid was added to each well and incubated (37°C, 20 min). The absorbance
of each solution was quantified on a Synergy 2 multi-detection microplate reader (BioTek,
Winooski, VT) at 800 nm, and the concentration of Pi was calculated using a phosphate
standard curve. The vanadate-sensitive ATPase activity was determined by subtracting the
concentration of Pi in an NaOV sample from the concentration of Pi in the respective
11

non-NaOV sample. Samples were plated in triplicate, and the average was determined.
For each condition, the fold-increase was calculated relative to the negative control.
2.6 Media and Cell Lines
MDCK cells (National Institutes of Health, Bethesda, MD) were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine
serum (FBS), 5 mM L glutamine, 50 units/mL penicillin, 50 μg/mL streptomycin,
4.5 g/L glucose, and 100 mg/L sodium pyruvate. MDCK-MDR1 cells (National Institutes
of Health, Bethesda, MD) were also maintained in the above media with the addition of
80 ng/mL colchicine in order to suppress the growth of cells not functionally expressing
the additional MDR1 gene into P gp present on the cell membrane85. All cultures were
maintained at 37°C in a humid atmosphere with 5% CO2 for six weeks, and were passaged
every 72 h.
2.7 Hoechst 33342 Accumulation Assay
P-gp is known to have two well-described bindings pockets. The first, called the
H-binding site, is characterized for its binding of Hoechst 33342. The rate of accumulation
of Hoechst 33342 in MDCK-MDR1 cells describes the binding pocket utilized by Aβ1-42
oligomers binding to P-gp.

MDCK-MDR1 cells were seeded at a density of

5 x 103 cells/well onto black sided 96-well tissue culture plates (Corning) and were
maintained for 48 h in DMEM, supplemented as described in Section 2.6. Cells were
subsequently treated with varying concentration of Aβ1-42 oligomers in 1% FBS media for
15 min prior to incubation with 10 μM Hoechst 33342 in 1% FBS media. Cells treated
with buffer equivalent (phosphate buffer, <0.5% DMSO) served as a vehicle. As a positive
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control, cells were treated with verapamil and paclitaxel. Fluorescence readings were
obtained using a Synergy 2 multi-detection microplate reader.
360 ± 40 nm

excitation and 485 ±

20 nm

emission was

Fluorescence at
measured under

temperature-controlled conditions (37°C) after a 90 min for equilibrium to be reached.
Results are reported as Hoechst 33342 accumulation relative to the control (Hoechst 33342
alone) ± SE.
2.8 Rhodamine 123 Accumulation Assay
The second P-gp binding site investigated was the R-binding site, characterized for
its binding to Rhodamine 123.

MDCK-MDR1 cells were seeded at a density of

5 x 103 cells/well onto black-sided 96-well tissue culture plates and were maintained in
DMEM, supplemented as described in Section 2.6. Cells were subsequently exposed to
varying concentrations of Aβ1-42 oligomers diluted in 1% FBS media and incubated (37°C,
30 min). Rhodamine 123 diluted in 1% FBS media was added to each well to achieve a
final concentration of 10 μM. Cells treated with buffer equivalent served as a vehicle. As
a positive control, cells were treated with cyclosporin A or paclitaxel. After an additional
incubation (37°C, 30 min), cells were washed three times with cold 12 mM phosphate
buffer (pH 7.4). 200 μL warm 12 mM phosphate buffer (pH 7.4) was added before
quantifying fluorescence readings with a Synergy 2 multi-detection microplate reader.
Fluorescence at 485 ± 20 nm excitation and 528 ± 20 nm emission was measured. Results
are reported as Rhodamine 123 accumulation relative to the control (Rhodamine 123
alone) ± SE.
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2.9 Cellular Transport Assay
To confirm the effect of Aβ oligomers on P-gp transport across a cell monolayer, a
cellular transport assay was implemented. MDCK-MDR1 cells were seeded at a density
of 1 x 104 cells/well onto the apical surface of a 24-well plate Thincert membrane (Grenier
Bio-one) with a 0.4 μm pore size, 1 x 108 cm-2 pore density, and 0.336 cm2 membrane
surface area. Cells were maintained for 4 days in DMEM, supplemented as described in
Section 2.6. Prior to the start and at the conclusion of the assay, TEER measurements were
performed across each membrane to ascertain monolayer integrity. To begin the assay,
each donor chamber was loaded with 10 μM Rhodamine 123 and in the presence or absence
of 2.5 μM Aβ1-42 oligomers in 1% FBS media, while the receptor chamber received
1% FBS media alone. 25 μL samples were removed from the receptor chamber at 1.5, 3,
4.5, and 6 h and replaced with an equal volume of 1% FBS media. The Rhodamine 123
fluorescence of each sample was quantified using a Synergy 2 multi-detection microplate
reader at 485 ± 20 nm excitation and 528 ± 20 nm emission.

Concentrations of

Rhodamine 123 were calculated using a standard curve and corrected for dilution. The
measured concentration of Rhodamine 123 was plotted versus time and a linear regression
was applied, where the slope is the rate of Rhodamine 123 appearance in the receptor
chamber (dC/dt). The apparent permeability, Pe, of Rhodamine 123 in the presence or
absence of Aβ1-42 oligomers is calculated by Equation 2.1:
𝑃𝑒 =

𝑑𝐶 𝑉
(
)
𝑑𝑡 𝐶0 𝐴

Equation 2.1

Here dC/dt is the rate of appearance of Rhodamine 123 in the receptor
chamber (μmol/s), V is the volume of the receptor chamber (cm3), C0 is the initial
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Rhodamine 123 concentration in the donor chamber (μM), and A is the surface area of the
membrane (cm2). Pe is calculated in both the basolateral to apical and apical to basolateral
directions. Because P-gp is located on the apical surface of cells, the net efflux can then
be determined as the ratio of these Pe values:
Net Efflux =

𝑃𝑒,𝐵→𝐴
𝑃𝑒,𝐴→𝐵

Equation 2.2

A net efflux greater than 1 shows active transport via P-gp.
2.10 Immunocytochemistry
To investigate the effect of Aβ species on P-gp cell surface expression,
immunocytochemistry was performed.

MDCK-MDR1 cells were seeded onto glass

coverslips at a density of 3 x 105 cells/well and maintained in DMEM supplemented as
described in Section 2.6. After 48 h, cells were treated with 0-0.01 μM Aβ aggregate
species. Following 6 h treatment, cells were fixed with 4% paraformaldehyde solution,
probed with anti-P-gp (F4), conjugated to Cy3, and stained with DAPI. Anti-P-gp (F4)
was specifically chosen due to its recognition of an extracellular loop ensuring that only
cell membrane bound P-gp was visualized without cell permeabilization.
Cells were imaged 24 h after mounting to slides with a Nikon Eclipse 80i
fluorescent microscope using a 40x objective. For each coverslip, 16 different fields of
view were captured for analysis of both the DAPI and TRITC channels. CellProfiler was
used to quantify the total number of cells using the DAPI images and determine the
fluorescence intensity of each cell using the TRITC images. Parameters used by the
pipeline were calibrated to statistically produce the same values as manual cell counts.
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2.11 Statistical Analysis
Prism 8 software (GraphPad Software, La Jolla, CA) was used for all statistical
analysis. For data sets with two groups an unpaired t-test was used for comparison between
samples. For data sets with multiple groups, a one-way analysis of variance (ANOVA)
was used with a post hoc Dunnett’s analysis to compare all samples to the respective
control. p<0.05 was considered significant. All values are expressed as the mean ± SE.
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CHAPTER 3
BINDING AND TRANSPORT OF Aβ BY P-GLYCOPROTEIN
3.1 Introduction
Defining the clearance mechanism for Aβ from the brain has been of interest in
recent years. The ability to target this mechanism could allow for increased removal of Aβ
early in the disease state. This reduction in Aβ in the brain would lead to less aggregated
Aβ because aggregation is a nucleation dependent process. Aβ is an amphipathic molecule
with hydrophobic amino acid residues concentrated in the C-terminal portion of the
peptide. Aβ is known to be a substrate of low-density lipoprotein receptor-related protein
1 (LRP-1)26,103–108. LRP-1 is expressed on the basolateral side of the BBB therefore this
allows Aβ to be transported from the brain into the endothelial cells. However, the
mechanism for transport out of the endothelial cells into the blood has not been fully
described. Some studies have indicated Aβ might be transported into the blood stream via
P-gp95–101. However, there is controversy on the conditions required for Aβ transport via
P-gp.

Some of this controversy may be due to lack of Aβ aggregate species

characterization.
P-gp, also known as multidrug resistance protein 1 (MDR1), is a membrane bound
efflux protein on the apical side of the BBB with a wide variety of amphipathic,
hydrophobic substrates, and therefore Aβ is an ideal candidate for transport44–47. A member
of the ATP-binding cassette transporter superfamily, P-gp is known to have to have 2
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“cassettes,” each with its own substrate binding site and ATP binding site connected via a
short peptide linker50,55–59,109. Currently, most studies have determined that P-gp substrates
enter the binding sites not from the cytoplasm but instead from the interior of the lipid
bilayer.
This chapter identifies and characterizes the P-gp binding capabilities of different
Aβ species, including monomer, oligomer, sonicated fibril, and fibril. Using an ATPase
activity assay, P-gp was illustrated to selectively bind Aβ oligomers. In order to further
elucidate the binding relationship between Aβ oligomers and P-gp, the preferred binding
site for Aβ oligomers was investigated. P-gp has two well-described binding sites, each
named for a fluorescent substrate. The H-binding site is characterized for its binding
relationship with Hoechst 3334257,61,68,72,73, while the R-binding site is characterized for its
binding to Rhodamine 12334,46,61,66,68,74–77.

An increase in cellular accumulation of

Rhodamine 123 in the presence of Aβ oligomers signifies Aβ oligomers interact with
P-gp’s R-binding site. However, in a cellular transport assay, this relationship was unable
to be confirmed. Together, this data displays P-gp’s selective binding to Aβ oligomeric
species with interaction occurring at the R-binding site but is unable to confirm an effect
on the directionality of Rhodamine 123 transport. These results exhibit the continued need
for further study of P-gp as a potential therapeutic target for AD.
3.2 Materials and Methods
3.2.1 Preparation of Aβ Aggregate Species
Aggregate species – monomer, oligomer, sonicated fibril, and fibril - were freshly
prepared as described, respectively, in Sections 2.2, 2.3, and 2.4.
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3.2.2 ATPase Activity Assay
To determine if Aβ aggregate species are interacting with the binding site of P-gp,
an ATPase activity assay was used as described in Section 2.5. Aβ monomer, sonicated
fibril, and fibril samples were evaluated at 1, 5, and 10 μM. Aβ oligomer samples were
evaluated at 0.5, 1, and 5 μM, reflecting the highest concentration of oligomer preparation
that remains stable. Results are reported as a fold increase of the ATPase activity relative
to buffer alone (VEH), and as the average ± SE.
3.2.3 Cell Culture
To explore the interactions between Aβ oligomers and P-gp in a cell model, both
MDCK and MDCK-MDR1 cell lines were used. The MDCK-MDR1 cell line is a variation
of the MDCK line that has been transfected to express additional human P-gp. As shown
in Figure 3.1, MDCK-MDR1 cells present significantly more P-gp (red staining) on the
cell membrane for transport than MDCK cells. Cells were seeded and maintained as
described in Section 2.6.
3.2.4 Hoechst 33342 Accumulation Assay
The interaction of Aβ oligomers with the H-binding site of P-gp was investigated
using a Hoechst 33342 accumulation assay as described in Section 2.7. MDCK-MDR1
cells were seeded and maintained as described in Sections 2.6 and 2.7. Paclitaxel and
verapamil (Figure 3.2) were each examined as positive controls; cells were treated with
1-40 μM paclitaxel or verapamil. 0.5-5 μM Aβ oligomers were evaluated to determine
their ability to interact with the H-binding site and increase Hoechst 33342 accumulation.
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Results are reported as a fold increase of Hoechst 33342 fluorescence accumulation relative
to cells treated with Hoechst 33342 alone (control) and as the average ± SE.
3.2.5 Rhodamine 123 Accumulation Assay
Potential interaction with the R-binding site of P-gp was determined using a
Rhodamine 123 accumulation assay as described in Section 2.8. MDCK-MDR1 cells were
seeded and maintained as described in Sections 2.6 and 2.8. Paclitaxel and cyclosporin A
(Figure 3.2) were each examined as positive controls; cells were treated with
1-40 μM paclitaxel or cyclosporin A. 0.5-5 μM Aβ oligomers were evaluated to determine
their ability to interact with the R-binding site and increase Rhodamine 123 accumulation.
Results are reported as a fold increase of Rhodamine 123 fluorescence accumulation
relative to a sample of Rhodamine alone (control) and as the average ± SE.
3.2.6 Rhodamine 123 Transport Assay
In order to confirm the directionality of Rhodamine 123 transport inhibition, a
Rhodamine 123 transport assay was performed as described in Section 2.9. MDCK-MDR1
cells were seeded and maintained as described in Sections 2.6 and 2.9. Rhodamine 123
was added to either the basolateral or apical compartment to measure transport across the
cellular monolayer, and treatment in the presence or absence of 2.5 μM Aβ oligomers
facilitated examination of R-binding site interactions. After treatment samples were taken
from the receiving chamber every 90 min over 6 h to quantify the transport rate of
Rhodamine 123 and calculate the apparent permeability, Pe, of Rhodamine 123 from
Equation 2.1 in both the basolateral to apical direction and the apical to basolateral
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direction, as well as the associated net efflux using Equation 2.2. Net efflux greater than 1
indicates active transport via P-gp. All values are reported as the average ± SE.
3.3 Results
3.3.1 Aβ oligomers bind P-glycoprotein
To evaluate the ability of different Aβ aggregate species to bind to P-gp, an ATPase
activity assay was used. Since P-gp is a transmembrane efflux transporter, inverted
vesicles with P-gp presenting to the bulk solution were used to determine binding to P-gp.
When P-gp vesicles were allowed to interact with Aβ monomer, sonicated fibril, and fibril,
insignificant ATPase activity was observed, indicating an absence of P-gp binding
(Figure 3.3). Aβ oligomer at 5 μM, however, shows a significant increase in ATPase
activity compared to the vehicle (Figure 3.3).

These results demonstrate that P-gp

selectively binds oligomeric Aβ.
3.3.2 Aβ oligomers exclusively interact with P-glycoprotein’s R-binding site
To determine whether Aβ oligomers interact with P-gp’s H-binding site or
R-binding site, Hoechst 33342 and Rhodamine 123 accumulation assays were used. In this
assay, when a potential substrate interacts with the H-binding site, more Hoechst 33342
will accumulate in the cell when compared to a solution with Hoechst 33342 alone (control)
due to the potential substrate competing with Hoechst 33342 for the available P-gp
H-binding sites. Similarly, when a potential substrate interacts with the R-binding site,
more Rhodamine 123 will accumulate in the cell compared to Rhodamine 123 alone
(control). Verapamil is known to bind to the H-binding site of P-gp and is shown here to
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significantly increase the accumulation of Hoechst 33342 in a dose dependent manner
(Figure 3.4C). Cyclosporin A is a known substrate of the R-binding site and shows a
significant increase of Rhodamine 123 accumulation (Figure 3.4D). Paclitaxel occupies
both the H- and R-binding sites of P-gp and induces a significant increase in both Hoechst
33342 and Rhodamine 123 accumulation (Figure 3.4E). Some cooperativity can also be
observed between the two sites. While Rhodamine 123 does not bind to the H-binding site,
it does significantly decrease the accumulation of Hoechst 33342 (Figure 3.4A). In
contrast however, the presence of Hoechst 33342, does not induce a change in Rhodamine
123 accumulation (Figure 3.4B).
When Aβ oligomers were introduced into these assays, the accumulation of
Hoechst 33342 was unaffected (Figure 3.4F). Therefore, Aβ oligomers do not appear to
interact with the H-binding site of P gp (Figure 3F). In contrast, the accumulation of
Rhodamine 123 increases significantly in the presence of 5 μM Aβ oligomers
(Figure 3.4F). These results demonstrate that Aβ oligomers exclusively interact with the
R-binding site of P-gp and do not present cooperativity with the H-binding site.
3.3.4 Aβ oligomers have minimal effect on Rhodamine 123 transport across a cell
monolayer
To confirm the directionality of transcellular Rhodamine 123 transport via P-gp and
examine the effect of Aβ on this transport, a cellular transport assay was performed in
MDCK-MDR1 cells. When Rhodamine 123 was added alone to the basolateral chamber
a Pe of 7.40 cm/s was measured. In contrast, addition of Rhodamine 123 to the apical
chamber led to a much smaller Pe of 1.76 cm/s, thus yielding a net efflux of 4.26. This net
efflux is representative of directional transport in the basolateral to apical direction. When
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this transport occurred in the presence of 2.5 μM Aβ oligomers, the permeability and the
net efflux of Rhodamine 123 in the basolateral to apical direction is slightly decreased
(Figure 3.5); however, this difference did not reach significance. These results demonstrate
the directionality of Rhodamine 123 transport but fail to confirm the interaction between
Aβ oligomers and the P-gp R-binding site in this cell configuration.
3.4 Discussion
Multiple studies report that Aβ interacts with P-gp95–101. However, these studies do
not compare the ability of different Aβ aggregate states to preferentially bind to P-gp. Here,
an ATPase assay was used to demonstrate that Aβ monomer, sonicated fibril (representing
soluble intermediates), and fibril do not bind P-gp, while Aβ oligomers exhibit significant
binding. Furthermore, Aβ oligomers were shown in a cellular assay to interact exclusively
with the R-binding site of P-gp. However, this interaction did not manifest in an assay
measuring directional transport across a cellular monolayer.
The lack of binding for the Aβ sonicated fibril and fibril could be due to the sizing
of the P-gp binding sites46,57,61–65. Specifically, due to the large size of the sonicated fibril
and fibril species, those aggregates may not be able to access the binding sites for transport.
The ability of smaller Aβ oligomeric species to bind P-gp may be potentially due to Aβ
oligomers’ ability to insert into the lipid bilayer. Some studies have shown that potential
P-gp substrates enter the binding sites through the lipid bilayer instead of directly from the
cytoplasm. Additionally, compared to monomer, oligomers present a hydrophobic surface,
which may aid in the oligomeric species’ preferential binding to P-gp.
P-gp has two well-described transmembrane binding sites, each named for a
fluorescent substrate. The H-binding site has been characterized for its binding with
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Hoechst 3334257,61,68,72,73, while the R-binding site has been characterized for its binding
with Rhodamine 12334,46,61,66,68,74–77. Potential substrates can bind either the H-binding site,
the

R-binding site,

or

both

to

be

transported

via

P-gp.

The

controls

(verapamil55,57,61,65,66,90,110–112, cyclosporin A55,57,111,113, paclitaxel55,61,111,114) illustrate this
binding ability with significant accumulation of Hoechst 33342, Rhodamine 123, or both,
respectively.
Additionally, it is shown that Rhodamine 123 and Hoechst 33342 bind only to their
respective sites with the possibility of a cooperative relationship between the two binding
sites. There is no difference in accumulation of Rhodamine 123 in the presence of Hoechst
33342. When measuring Hoechst 33342 accumulation in the presence of Rhodamine 123,
there is a decrease in Hoechst 33342 accumulation, which has been previously studied68.
This result shows that there can be a cooperative binding relationship between the two
binding sites; however, it is not required to have both binding sites occupied for transport
to occur. In the case of Aβ oligomers, there is no interaction with the H-binding site, unlike
the trends seen with verapamil55,57,61,65,66,90,110-112, only with the R-binding site, shown by
the increase in Rhodamine 123 accumulation similar to the behavior exhibited by
cyclosporin A55,57,111,113.

Additionally, since there is no decrease in Hoechst 33342

accumulation in the presence of Aβ oligomers, there is not a cooperative binding
relationship. This adds Aβ oligomers to the list of P-gp substrates that exclusively interact
with the R-binding site including cyclosporin A, Rhodamine 123, and others.
The effect of Aβ on directional transport was explored by examining
Rhodamine 123 transport via P-gp across a cell monolayer. While directional transport of
Rhodamine 123 was confirmed, the reduction of this transport in the presence of Aβ
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oligomers does not reach significance. However, the highest manageable concentration in
this experiment is lower than that used in the ATPase activity assay and cellular
accumulation assays, which did show significant interaction with P-gp.
This study has shown that Aβ oligomers are able to bind to P-gp, instigating the
conformational shift for substrate transport. However, other Aβ aggregate species do not
show a similar binding ability. Additionally, this work demonstrates that Aβ oligomers
interact with the R-binding site of P-gp by decreasing the transport of Rhodamine 123.
Together, these findings illustrate the potential of P-gp to be a novel therapeutic target for
AD.
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Figure 3.1 P-gp expression and function in MDCK-MDR1 and MDCK cells.
MDCK-MDR1 cells are MDCK cells transfected to overexpress P-gp. MDCK-MDR1
cells (panels A, D) exhibit more P-gp staining than MDCK cells (panels B, E). The
basolateral to apical permeability coefficient of Rhodamine 123 across a cellular
monolayer is greater in MDCK-MDR1 cells than in MDCK cells due to the presence of
additional P-gp (panel C).
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Figure 3.2 Structures of P-gp substrates. Structures of Rhodamine 123 (panel A),
Hoechst 33342 (panel B), verapamil (panel C), cyclosporin A (panel D),
paclitaxel (panel E), each is a substrate of P-gp.
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Figure 3.3 ATPase activity of Aβ aggregate species. Aβ monomer (circles), oligomers
(diamonds), sonicated fibrils (triangles), and fibrils (squares) were incubated in the
presence of inverted P-gp vesicles and MgATP for 20 min. ATPase activity was calculated
from Pi generation and reported as a fold increase relative to buffer alone (VEH) indicated
by a dashed line and indicative of no binding to P-gp. Error bars indicate SEM, n=3-4. *
p<0.05.
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Figure 3.4 Cellular accumulation of Hoechst 33342 or Rhodamine 123 in the presence
of alternate P-gp substrates. MDCK-MDR1 cells were pre-incubated in the presence of
a competing P-gp substrate, Rhodamine 123 (panel A), Hoechst 33342 (panel B),
verapamil (panel C), cyclosporin A (panel D), paclitaxel (panel E), or Aβ oligomers (panel
F). 10 μM Hoechst 33342 (open bars) or 10 μM Rhodamine 123 (closed bars) were added
to the cells, and incubation continued for 90 or 30 min, respectively to allow for equilibrium
to be attained. Fluorescence accumulation is reported as a fraction of the control (Hoechst
33342 or Rhodamine 123 alone), represented by the dashed line at 1 and indicative of basal
dye accumulation. Error bars indicate SEM, n=2-4. * p<0.05, ** p<0.01, *** p<0.001,
**** p<0.0001.
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Figure 3.5 Permeability coefficient and net efflux of Rhodamine 123 across
MDCK-MDR1 monolayers.
Rhodamine 123 transport was measured across
MDCK-MDR1 monolayers in the presence and absence of 2.5 μM Aβ oligomers. Cells
were grown on a suspended membrane. Following formation of a confluent monolayer,
Rhodamine 123 was added to either the basolateral (solid bars) or apical (open bars)
chamber. A) Samples were removed from the opposite chamber every 90 min over 6 h to
calculate the transport rate of Rhodamine 123 into the receiving chamber. Results are
reported as the permeability coefficient, calculated from the transport rate as described in
Equation 3.1. B) Net efflux is the ratio of the permeability coefficient in the basolateral to
apical direction and the permeability coefficient in the apical to basolateral direction.
Results are reported as the average. Error bars indicate SEM, n=4.
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CHAPTER 4
REDUCTION OF P-GLYCOPROTEIN TRANSPORT VIA Aβ
4.1 Introduction
One potential clearance mechanism for Aβ from the brain is via P-gp, a membrane
bound efflux protein located on the apical side of the BBB28,115,116. A minimal presence of
P-gp on the BBB has been correlated to a localized high incidence of Aβ plaques 93,94.
While the decreased presence of P-gp could cause the increased concentration of Aβ, other
studies demonstrated that Aβ is able to influence P-gp cell surface presence102,117–120.
Specifically, one study concluded that treatment with Aβ solutions initiated signaling for
P-gp degradation via the ubiquitin-proteasome pathway102.
This chapter investigated whether various Aβ aggregate species are responsible for
initiating P-gp degradation and examines the subsequent effect on transport. In order to
determine the effect of different Aβ species, cell membrane P-gp is probed using
immunocytochemistry. Additionally, cellular accumulation assays are used to ascertain
any effect of the Aβ treatments on the ability of P-gp to transport well known substrates.
Finally, the effect on directional transport by P-gp across a cell monolayer is probed.
In an MDCK-MDR1 cell culture model, none of the Aβ aggregate species explored
demonstrated any effect on the presence of P-gp on the cell membrane. In order to further
investigate the transport capabilities of P-gp after treatment with Aβ species, a cellular
accumulation assay was performed following Aβ treatment. Again, none of the Aβ species
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revealed any difference in cellular accumulation of P-gp substrates.

In the cellular

transport assay, however, each of the Aβ species tested had a deleterious effect on the net
efflux of Rhodamine 123. Uniquely, this assay allows cell treatment at the basolateral
surface to more directly mimic the conditions of the diseased brain.
Together, this data describes an interesting relationship between P-gp and Aβ.
When Aβ is present at the apical surface of a cellular monolayer, the presence of P gp is
unaltered. However, when the Aβ species are present at the basolateral surface of the cell,
consistent with pathology in the AD brain, the transport via P-gp is reduced. These results
exhibit the complexity of the relationship between Aβ and P-gp and the need for further
study of this relationship to fully understand the role of P-gp in the AD brain.
4.2 Materials and Methods
4.2.1 Preparation of Aβ Aggregate Species
Aggregate species – monomer, oligomer, protofibril mix, and fibril – were freshly
prepared as described, respectively, in Sections 2.2, 2.3, and 2.4.
4.2.2 Cell Culture
To explore the interactions between Aβ aggregates and P-gp in a cell model, the
MDCK-MDR1 cell line was used. Cells were seeded and maintained as described in
Section 2.6.
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4.2.3 Immunocytochemistry
To determine the impact of extended treatment with Aβ aggregates on the available
membrane-bound P-gp, immunocytochemistry was used as described in Section 2.10.
MDCK-MDR1 cells were seeded onto coverslips and maintained as described in Section
2.6 and 2.10. Cells were treated for 6 h with 0-0.01 μM Aβ aggregate species on the apical
surface. After treatment, cells were fixed and stained with DAPI and an anti-P-gp (F4), a
P-gp antibody which binds to an extracellular loop of P-gp. Images were analyzed with
CellProfiler to quantify P-gp signal per cell. Average values are reported as P-gp per cell
relative to the vehicle ± SE.
4.2.4 Hoechst 33342 and Rhodamine 123 Accumulation Assays
To determine if extended Aβ treatment leads to a reduction in functional P-gp
present on the cell membrane, a Hoechst 33342 or Rhodamine 123 accumulation assay was
used as described in Section 2.7 and 2.8. MDCK-MDR1 cells were seeded and maintained
as described in Sections 2.6, 2.7, and 2.8. Cells were treated on the apical surface with
0-0.01 μM Aβ aggregates for 6 h prior to introduction of Hoechst 33342 or Rhodamine and
assessment of accumulation. A decrease in accumulation compared with the vehicle would
attest to a reduction in functional P-gp in the presence of Aβ aggregate species. Results
are reported as a fold increase of Hoechst 33342 or Rhodamine 123 fluorescence
accumulation relative to the vehicle and as the average ± SE.
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4.2.5 Rhodamine 123 Transport Assay
In order to explore the effect of extended Aβ treatment on directionality of the
transport of Rhodamine 123 via P-gp, a Rhodamine 123 transport assay was used as
described in Section 2.9. MDCK-MDR1 cells were seeded and maintained as described in
Sections 2.6 and 2.9. MDCK-MDR1 monolayers were treated with in the presence or
absence of 0.001 μM Aβ aggregates for 6 h in the basolateral chamber to mimic the amyloid
plaques’ location in the brain. After the treatment was removed, 10 μM Rhodamine 123
solution was placed in either the apical or basolateral chamber to measure Rhodamine 123
transport across the cellular monolayer. Samples were taken every 90 min over 6 h to
quantify the transport rate of Rhodamine 123 and calculate the apparent permeability, Pe,
of Rhodamine 123 from Equation 2.1 in the basolateral to apical direction and the apical
to basolateral direction, as well as the associated net efflux using Equation 2.2. Net efflux
greater than 1 indicates active transport via P-gp.

All values are reported as the

average ± SE.
4.3 Results
4.3.1 Aβ aggregates do not affect the presence of P-gp on the cell membrane
In order to quantify the change in the presence of P-gp present on the cell
membrane, immunocytochemistry was used.

The anti-P-gp chosen binds to an

extracellular loop of P-gp allowing for exclusive visualization of the protein embedded in
the cell membrane instead of the total protein after permeabilizing the membrane. After
treating the apical surface of the cells with 0.001-0.01 μM Aβ oligomer, fibril mix, and
fibril, cells displayed no difference in P-gp present on the cell membrane (Figure 4.1).
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4.3.2 Aβ aggregates do not affect the accumulation of either Hoechst 33342 or Rhodamine
123
The functionality of P-gp present on the cell membrane was examined with a
Hoechst 33342 or Rhodamine 123 accumulation assay. In this assay, the accumulation of
the fluorescent substrate was compared between cells which had received 0-0.01 μM Aβ
monomer, oligomer, protofibril mix, or fibril. Cells probed with Hoechst 33342 exhibit no
additional accumulation compared with the vehicle (Figure 4.2A).

Likewise, cells

examined with Rhodamine 123, showed minimal accumulation difference from the vehicle
(Figure 4.2B).
4.3.3 Aβ aggregates effect the net efflux of Rhodamine 123
To evaluate the effect of Aβ aggregate species when treating the basolateral surface
of the cells, mimicking the situational environment of AD at the BBB, a Rhodamine 123
transport assay was used.

Minimal differences appear in the apical to basolateral

permeability coefficient for any of the treatments compared to the vehicle (Figure 4.3A,
open bars), while there are slight differences exhibited in the basolateral to apical
permeability coefficients compared to the vehicle (Figure 4.3A, closed bars). When
considering the net effluxes of each treatment, there is a clear difference between each of
the Aβ aggregate species and the vehicle treatment.
4.4 Discussion
Previously, an inversely correlative relationship was described between Aβ plaques
and P-gp at the BBB93,94. Later, it was demonstrated Aβ had a deleterious effect on the
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presence of P gp on the cell membrane102,117,119–121. However, this study did not fully
investigate the different Aβ aggregate states that were responsible for this effect. Here, the
purpose is to compare the effect of Aβ aggregate species on the presence of P-gp on the
cell membrane. While Aβ treatment at the apical surface of cells did not yield any effect
on P-gp presence at the cell membrane, when MDCK-MDR1 cells are treated at the
basolateral surface, a reduction of transport via P-gp is observed.
Immunocytochemistry and cellular accumulation assays indicate that there is no
difference in either P-gp cell surface expression or P-gp substrate accumulation after
treatment with Aβ aggregate species. Two potential explanations for this result are either
Aβ does not influence the presence of P-gp on the cell membrane and its transport abilities,
or Aβ is unable to instigate its potential reductive effects from the apical surface of these
cells.
In order to test the hypothesis that Aβ’s reductive influence on P-gp requires action
on the basolateral surface of the cells, MDCK-MDR1 cells were grown on a suspended
semi-permeable membrane to allow treatment at the basolateral surface. Here, the net
efflux of Rhodamine 123 was reduced following each Aβ species treatment, demonstrating
the deleterious effect of Aβ.
BBB endothelial cells are known to exhibit apicobasal polarity where the lipid and
protein composition of the cell membrane is highly dependent on location122. While these
experiments were performed in non-brain microvasculature endothelial cells,
MDCK-MDR1 cells do display polarity, especially when grown on a suspended
membrane83,86. Thus, the trends shown here in MDCK-MDR1 cells exploiting the polarity
of the cellular structure may be increased in a BBB endothelial model.
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Together, this study illustrates the importance of mimicking the local conditions in
the diseased brain due to the intrinsic polarity of the cells. Additionally, it conveys the
need for further inquiry into the role P-gp plays in the AD disease state.
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Figure 4.1 P-gp presence on the cell membrane after Aβ treatment. MDCK-MDR1
cells grown on coverslips were treated with 0.001 μM (closed bars) or 0.01 μM (open bars)
Aβ oligomer, fibril mix or fibril for 6 h. Cells were then washed, fixed, and probed with
DAPI and anti-P-gp (P7965) conjugated to Cy3. Images were analyzed using CellProfiler
to determine Cy3 staining per cell relative to the cells treated with buffer alone (VEH)
represented by a dashed line at 1. Error bars represent SEM, n=2-3.
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Figure 4.2 Cellular accumulation of Hoechst 33342 or Rhodamine 123 in
MDCK-MDR1 cells after treatment with Aβ treatment. MDCK-MDR1 cellular
monolayers were treated with 0.001 μM (closed bars) or 0.01 μM (open bars) Aβ
monomer, oligomer, protofibril mix or fibril for 6 h, then washed.
10 μM Hoechst 33342 (panel A) or 10 μM Rhodamine 123 (panel B) was added to the
cells for 30 or 90 min, respectively to allow for equilibrium to be attained. Fluorescence
accumulation is reported as a fraction of the vehicle, represented by a dashed line at 1.
Error bars represent SEM. n=2.
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Figure 4.3 Permeability and net efflux across MDCK-MDR1 cellular monolayers
after Aβ treatment. MDCK-MDR1 monolayers grown on a suspended membrane were
treated with buffer (VEH) or 0.001 μM Aβ monomer (MON)), oligomer (OLIG),
protofibril mix (P MIX), or fibril (FIB), for 6 h via addition of Aβ to the basolateral
chamber. After treatment, Rhodamine 123 was added to either the basolateral or apical
chamber. A) Samples were removed from the opposite chamber every 90 min over 6 h to
calculate the permeability coefficient in the basolateral to apical direction (solid bars) and
the apical to basolateral direction (open bars). B) These permeability coefficients were
used to calculate the net efflux. n=2.
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CHAPTER 5
CONCLUSIONS
With an aging population, in addition to the increase in average life-span, the
number of AD cases will only continue to increase. As of 2018, 5.8 million Americans are
living with Alzheimer’s disease, this number is expected the increase to almost 14 million
by the year 20501. Since the only current medications available for AD patients treat the
symptoms and not the underlying disease pathology, the need for a therapeutic is urgently
increasing as well. In conjunction, a more complete understanding of the underlying
disease state is required in order to properly target those therapeutics. Fully describing the
clearance mechanism of AD’s Aβ species is one pathway to a more fundamental
understanding of the disease state. Therefore, this study aimed to elucidate the relationship
between P-gp and Aβ.
In Chapter 3, it was demonstrated that P-gp selectively binds to Aβ oligomeric
species. Additionally, Aβ oligomers were verified as selectively interacting with P-gp’s
R-binding site, indicated by increased accumulation of Rhodamine 123 but not
Hoechst 33342 in a cellular monolayer. However, when investigating the directional
Rhodamine 123 transport across a cellular monolayer, competition with Aβ oligomers for
the R-binding site could not be confirmed.
In Chapter 4, the effect of all Aβ species on the presence of P-gp on the cell
membrane was analyzed. When measuring P-gp’s cell membrane presence both directly,
via immunocytochemistry, and indirectly, via cellular accumulation and transport, an
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interesting trend emerged within immunocytochemistry and cellular accumulation assays,
the apical surface of the cellular monolayer was treated with the Aβ species. In all cases,
there was no significant alteration in P-gp presence compared with the vehicle, regardless
of the aggregate species. However, in the cellular transport assay, the cellular monolayers
are grown on a suspended semi-permeable membrane, making the basolateral surface of
the cells available for treatment. In these cellular transport assays, a difference in transport
capabilities was observed between the vehicle and each Aβ species. This variance in results
correlating with the cell surface treated is especially interesting when considering the
disease state. P-gp is located on the apical surface of the brain microvasculature, while the
Aβ plaques as well as smaller aggregates are located at the basolateral surface of those
capillaries. The cellular transport assay best represents what is potentially occurring in the
brain during the disease state.
In summary, this study has characterized Aβ’s interaction with P-gp in two distinct
pathways. First, results demonstrated P-gp selectively interacting with Aβ oligomers at the
R-binding site as a potential clearance mechanism. Second, experimentation probed a
possible deleterious relationship between Aβ species and P-gp’s presence on the cell
membrane. These findings will direct future work investigating P-gp as a potential
therapeutic target for AD.
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CHAPTER 6
FUTURE PERSPECTIVES
While Aβ oligomeric species have been illustrated to interact with P-gp’s R-binding
site in this study, this interaction was defined by a reduction in Rhodamine 123 transport.
In order to conclusively show that Aβ oligomers are transported via P-gp, a more direct
measurement of Aβ oligomers needs to occur. One potential solution is the labelling of Aβ
in order to directly measure its binding and transport. However, the aggregation abilities
of pre-labelled monomeric Aβ are not well studied and it is believed that the
oligomerization sites might be altered by the conjugated fluorescent dye. Additionally, the
labelling of oligomeric Aβ was investigated during the course of this study. This was
ultimately unsuccessful due to the low protein yield and high excess dye concentration
present in the samples. Alternatively, current protocols utilize sandwich ELISAs, which
are not without their own difficulties. These assays leverage antibodies that can have issues
recognizing Aβ oligomers due to potentially masked binding sites. This complication
might be solved with dissociation of oligomeric aggregates in basic buffer. Future work
will explore these possibilities to confirm Aβ oligomeric transport before P-gp can serve
as a potential therapeutic target for AD.
Additionally, these findings should be verified in a BBB cell system and
animal-based models. As stated previously, the MDCK/MDCK-MDR1 cell models are
able to model the function of P-gp as seen on the BBB, but as canine kidney cells they do
not exhibit all of the functions of the human BBB. The first step would be to verify the
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transport findings in a primary human brain microvascular endothelial cell (HBMVEC)
model. Then, continue into a mouse model overexpressing a human MDR1 gene such as
hMDR1-MAC due to the differences between mouse and human P-gp specifically in
transport across the BBB109.
With positive future work results, P-gp should be investigated as a potential
therapeutic target for AD.

The loss of P-gp transport across the cell membrane,

demonstrated in Chapter 4, will need to be attenuated in order to preserve BBB clearance
mechanisms, not only for Aβ but for other potentially harmful substrates as well. Some
work has identified potential P-gp cellular presence stimulators123,124. Continuing this
work will be a novel therapeutic target for AD research. Many previous therapeutic targets
have focused on Aβ production or the Aβ aggregation pathway, and these targets required
bioactive agents to pass the BBB. With a goal of recovering P-gp levels, the target instead
would be the cells of the BBB itself, offering an easier delivery mechanism.
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